Tesamorelin
Also known as: Egrifta
Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.
Approved uses
- HIV-associated lipodystrophy
Approved with human trials
Tesamorelin is an approved GHRH analog with randomized human trial data for HIV-associated lipodystrophy.
Approved medication with substantial human clinical evidence.
Evidence basis
- Human randomized trials
- FDA-regulated labeling
- Approved indication
Key references
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Tesamorelin guides
Read the matching guide or adjacent research pages for more context.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Ipamorelin
NNC 26-0161
Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.
CJC-1295
DAC:GRF
Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.
Category hub
Open the category page for the full comparison table and FAQ.